• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

    12/11/24 8:00:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KZIA alert in real time by email

    SYDNEY, Dec. 11, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development, announced that data from two abstracts will be presented at the San Antonio Breast Cancer Symposium highlighting the activity the Company's lead product candidate, paxalisib, for the potential treatment of immunotherapy-resistant triple negative breast cancer (TNBC) and HER2 positive metastatic breast cancer with active brain metastases.

    Kazia Therapeutics Limited Logo (PRNewsfoto/Kazia Therapeutics Limited)

    "Immunotherapy-resistant triple negative breast cancer represents one of the most difficult-to-treat areas of breast cancer, with a growing number of patients who have failed standard-of-care immunotherapy and require new treatment options," said John Friend, M.D., President and Chief Executive Officer of Kazia Therapeutics. "These new preclinical data highlight the potential therapeutic synergies between paxalisib and the checkpoint inhibitor, pembrolizumab (KEYTRUDA®), when used in combination in a preclinical model of immunotherapy-resistant triple negative breast cancer. Furthermore, these data also show synergies when paxalisib is combined with the PARP inhibitor, olaparib (LYNPARZA®), which is approved for the treatment of advanced BRCA-mutated HER2 negative metastatic breast cancer.

    "In a second abstract, clinical investigators presented efficacy and safety data in heavily pretreated patients (median prior 8 lines of therapy) with HER2 positive breast cancer with active brain metastases. Although the primary endpoint of overall response rate (ORR) was not met, patients receiving a combination of paxalisib and trastuzumab (ENHERTU®) had a median overall survival of 16.5 months, which compares favorably versus historical control studies."    

    Presentation Details:  

    Abstract Number:  

    SESS-2122



    Title (P3-06-27):   

    Immunotherapy and PI3K/mTOR inhibition combination to mediate metastasis and immunotherapy resistance in triple-negative breast cancer



    Presenting Author: 

    John Friend, M.D.



    Date/Time:      

    December 12, 2024, 12:00-2:00 pm CT 



    Conclusions: The addition of paxalisib to immunotherapy in the 4T1 TNBC mouse model reduced primary tumor burden, lung metastases, and liver inflammation whilst overcoming toxicity complications and resistance associated with standard-of-care immunochemotherapy. Paxalisib in combination with the PARP inhibitor olaparib, but not monotherapy alone, also reduced primary tumor burden and metastases. Moving forward, work is ongoing to elucidate the PI3K-mTOR mechanism of overcoming metastasis and drug resistance as well as the translation of the data into a clinical development program for patients with TNBC and advanced breast cancer.

    Abstract Number: 

    SESS-1433



    Title (P5-05-04): 

    Final results of a phase II trial evaluating paxalisib with trastuzumab for patients (pts) with HER2 positive metastatic breast cancer with active brain metastases.



    Presenting Authors:

    Jose Leone and Co-Author(s): Jose Pablo Leone, Noah Graham, Nabihah Tayob, Heather A. Parsons, Jorge Gomez Tejeda Zañudo, Raechel Davis, Molly K. DiLullo, Jennifer A. Ligibel, Filipa Lynce, Jing Ni, Eric P. Winer, Jean Zhao, Rinath M. Jeselsohn, Nancy U. Lin



    Date/Time:    

    December 13, 2024, 12:30-2:00 pm CT



    Conclusions: In this heavily pre-treated population of pts with HER2+ active BCBM, the combination of paxalisib 30 mg daily with trastuzumab was feasible, with a toxicity profile consistent with a class effect of PI3K/mTOR inhibitors. However, it was associated with minimal clinical activity.

    About Kazia Therapeutics Limited

    Kazia Therapeutics Limited (NASDAQ:KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2 study in glioblastoma reported early signals of clinical activity in 2021, and a pivotal study in glioblastoma, GBM AGILE, has been completed and a Type C meeting with the FDA is scheduled in December 2024. Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the FDA in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research Symposium in September 2024. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx.

    Forward-Looking Statements

    This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia's clinical and preclinical trials, Kazia's strategy and plans with respect to its programs, including paxalisib and EVT801, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory agencies, and the potential market opportunity for paxalisib. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia's Annual Report, filed on form 20-F with the United States Securities and Exchange Commission, or the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.

    This announcement was authorized for release by Dr John Friend, CEO.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kazia-therapeutics-to-present-data-highlighting-synergistic-activity-between-paxalisib-and-immunotherapy-in-immunotherapy-resistant-triple-negative-breast-cancer-model-at-the-san-antonio-breast-cancer-symposium-302328604.html

    SOURCE Kazia Therapeutics Limited

    Get the next $KZIA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KZIA

    DatePrice TargetRatingAnalyst
    2/6/2025$3.00Buy
    Maxim Group
    10/14/2021$18.00Buy
    Maxim Group
    More analyst ratings

    $KZIA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

      Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil SYDNEY, March 31, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to Cantrixil for USD $1 million.  In March 2021, Vivesto licensed the exclusive global development and commercialization rights for Cantrixil from Kazia Therapeutics. Having decided not to pursue development of Cantrixil in ovarian cancer, as originally anticipated under the license, Vivesto is currently exploring Cantri

      3/31/25 7:30:00 AM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease

      SYDNEY, Feb. 20, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced a research grant awarded from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to fund research between The Hebrew University of Jerusalem (Hebrew University) and Kazia to explore the therapeutic potential of paxalisib as a treatment for Parkinson's disease (PD). The grant will fund collaborative preclinical studies at Professor Ronit Sharonʼs lab (Hebrew University) aimed at establishing an operat

      2/20/25 8:46:00 AM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

      SYDNEY, Jan. 30, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. This novel treatment combination offers what is believed to be a unique approach to targeting this highly aggressive and treatment-resistant type of breast cancer. The ABC-Pax (Advanced Breast Cancer – Paxalisib) study is the first known trial conducted to assess the safety and ef

      1/30/25 7:30:00 AM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZIA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Kazia Therapeutics with a new price target

      Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $3.00

      2/6/25 7:53:38 AM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Kazia Therapeutics with a new price target

      Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $18.00

      10/14/21 8:02:40 AM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZIA
    SEC Filings

    See more
    • SEC Form 424B3 filed by Kazia Therapeutics Limited

      424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

      4/15/25 8:35:50 AM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Kazia Therapeutics Limited

      424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

      4/15/25 8:32:46 AM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Kazia Therapeutics Limited

      424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

      4/15/25 8:29:23 AM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZIA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

      SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

      11/14/24 4:19:36 PM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Kazia Therapeutics Limited

      SC 13G - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

      11/6/24 7:53:45 PM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

      SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

      8/12/24 7:28:02 PM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZIA
    Leadership Updates

    Live Leadership Updates

    See more
    • KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

      SYDNEY, Jan. 18, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive, Mr. Robert Apple to Kazia's Board of the Directors (the "Board") as a Non-Executive Director. Mr. Apple brings more than 25 years of senior leadership experience in the pharma industry to Kazia, including 16 years with Antares Pharma, Inc. ("Antares") as Senior Vice President, Chief Financial Officer and Corporate Secretary, and went on to serve as President and Chief Executive Officer

      1/18/24 7:30:00 AM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER

      SYDNEY, Dec. 13, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of Karen Krumeich as Chief Financial Officer. In this role, Ms Krumeich will focus on building and maintaining relationships with US investors, on preparing the company for future expansion, and on raising the profile of Kazia in global markets. Ms Krumeich is based in Pennsylvania in the United States and will formally commence work with Kazia in January 2022. Kazia CEO, Dr. James Garner, commented, "

      12/13/21 11:00:00 AM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

      SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and for collaborating with clinicians and scientists to advance the company's research programs. Dr. Friend is based in New Jersey in the United States. Kazia CEO, Dr. James Garner, commented, "We are delighted to welcome John to the Kazia team. With paxalisib moving rapidly towards potential commercialization, and EVT801 now in the clin

      11/15/21 11:00:00 AM ET
      $CLRB
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care